Explore hmg calculator-entry dose, vial-size, BAC-water and self-reported frequency distributions. Research context is separate from live observations.
Anonymized hmg calculator entries are summarized by each chart's selected period. Frequency responses come from the separate vial-duration feature. Inputs are not verified administrations or unique people.
HMG (menotropin) is a urine-derived mix of the fertility hormones FSH and LH, approved as Menopur and sourced in research for ovulation and ovarian-stimulation studies. It ships as a lyophilized powder reconstituted before use.
HMG provides direct FSH (driving follicular recruitment and growth) and LH (supporting theca-cell androgen production for granulosa-cell aromatisation) — replacing or supplementing endogenous pituitary gonadotropins in patients whose own HPG axis is insufficient or has been suppressed.[1] In men with hypogonadotropic hypogonadism, HMG (or HCG used to provide the LH signal) restores Leydig-cell testosterone production and supports spermatogenesis when combined with FSH activity.[2]
HMG is established standard-of-care for ovulation induction in WHO Group II anovulatory infertility and as part of controlled ovarian stimulation in IVF.[1][3] In male hypogonadotropic hypogonadism, combined HCG + HMG (or HCG + FSH) restores spermatogenesis in ~80% of treated men, summarised in the Rastrelli meta-analysis.[2] Off-label community use as part of "PCT" protocols after anabolic-androgenic-steroid cycles is widespread but not supported by controlled-trial evidence.
FDA-approved (Menopur for ovulation induction and IVF). Off-label community use for male fertility support and PCT is not an approved indication.
HMG has a reported half-life of ~37 hours (FSH component). The pharmacokinetic reference models an interval of once daily; this is not a measured community cadence or a dosing recommendation. The FSH component has a long half-life, so daily menotropin dosing builds up over several days to a working level; the LH activity clears faster. Pharmacokinetic source: FDA label (Menopur / menotropins) human PK. It is catalogued under Muscle Peptides on WPA.
3 HMG reconstitution calculations have been logged by the WPA community.
This is the lifetime header population. Each chart and its associated analysis below use their own selected period and denominator; frequency responses are a separate cohort.
These figures come from anonymized WPA peptide calculator sessions, not verified administrations or unique people. Separate modal inputs do not establish a joint protocol. They are community input statistics — not dosing recommendations, and not medical advice.
WPA Analysis
HMG (Human Menopausal Gonadotropin) is a naturally derived gonadotropin preparation containing both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) biological activity, traditionally extracted from the pooled urine of postmenopausal women — the source of the compound's name, since postmenopausal urine contains elevated gonadotropins due to the loss of ovarian negative feedback. HMG has been used clinically in assisted reproductive technology (ART) since the early 1960s, and the pharmaceutical history of the class runs through two major product generations: the original urinary-derived preparations (Pergonal by Serono, later Menopur by Ferring, which replaced early uHMG with a highly purified presentation) and the recombinant FSH preparations (recombinant FSH without LH, such as Gonal-F and Puregon) that displaced much of the uHMG market in the 2000s for pure-FSH indications. HMG's retained clinical role is specifically in protocols where combined FSH + LH activity is therapeutically necessary: most importantly, hypogonadotropic hypogonadism (Kallmann syndrome and idiopathic HH) in males, where LH is required to stimulate Leydig cell testosterone production concurrent with FSH-driven spermatogenesis, and in poor responders in IVF where LH supplementation may benefit follicular development.
In the male reproductive endocrinology context, HMG is used alongside hCG (as an LH-surrogate) for spermatogenesis induction in hypogonadotropic hypogonadism — the Büchter et al. (1998) and subsequent protocols that established subcutaneous hCG + HMG as standard of care for fertility induction in HH. In the ART context, Menopur (Ferring) — a highly purified urinary HMG containing 75 IU FSH and 75 IU LH per vial — is the dominant modern HMG product and the reference presentation for the reconstitution data below. HMG holds FDA approval (Menopur for IVF superovulation) and EMA approval across multiple indications, making it one of the few compounds on this site with a formal regulatory approval in reproductive medicine.
Research background is separate from the calculator observations below. Calculator entries do not establish administration, safety, effectiveness, or the reasons for an input.
WPA DOSING INSIGHT
The summaries use each chart's own period and, for frequency responses, its dose filter. Separate cohorts must not be combined into a protocol.
WPA RECONSTITUTION INSIGHT
Vial-size and BAC-water observations describe separate input distributions, not purchases or verified preparations. Separate modal inputs do not establish a joint protocol.
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.